CreativeOne Wealth LLC Increases Position in Stryker Corporation $SYK

Key Points

• CreativeOne Wealth LLC increased its holdings in Stryker Corporation by 72.7% during the first quarter, owning 4,465 shares worth approximately $1.66 million as of the latest filing.
• Director Ronda E. Stryker sold 200,000 shares valued at over $75 million, reducing her ownership stake by 5.84%.
• Stryker's most recent earnings report showed an EPS of $3.13, exceeding expectations and reflecting a revenue growth of 11.1% year-over-year.

CreativeOne Wealth LLC raised its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 72.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,465 shares of the medical technology company's stock after purchasing an additional 1,879 shares during the quarter. CreativeOne Wealth LLC's holdings in Stryker were worth $1,662,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Stryker by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company's stock valued at $12,306,572,000 after acquiring an additional 361,136 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company's stock worth $4,515,847,000 after purchasing an additional 1,021,496 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Stryker by 13.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company's stock worth $838,640,000 after purchasing an additional 261,058 shares during the last quarter. GAMMA Investing LLC raised its position in Stryker by 43,226.8% during the 1st quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company's stock worth $772,390,000 after purchasing an additional 2,070,133 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Stryker by 1.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,015,374 shares of the medical technology company's stock worth $750,223,000 after purchasing an additional 30,329 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on SYK shares. Evercore ISI raised their target price on Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 8th. Sanford C. Bernstein set a $450.00 target price on Stryker in a research report on Monday, May 5th. JMP Securities reissued a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. BTIG Research reissued a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Finally, Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. Fifteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $430.10.

Stryker Stock Up 0.5%

Stryker stock traded up $1.81 during midday trading on Friday, reaching $391.48. The stock had a trading volume of 672,496 shares, compared to its average volume of 1,150,000. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The company has a market capitalization of $149.67 billion, a P/E ratio of 51.85, a PEG ratio of 2.85 and a beta of 0.93. The company has a fifty day moving average price of $389.26 and a two-hundred day moving average price of $379.33. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same period in the previous year, the company posted $2.81 EPS. The firm's revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker's payout ratio is presently 44.50%.

Insider Transactions at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of Stryker stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.